Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.85 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.85 |
| ▸ | EGFR | P00533 | 1/20 | 0.85 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.85 |
| ▸ | TEC | P42680 | 1/20 | 0.85 |
| ▸ | TXK | P42681 | 1/20 | 0.85 |
| ▸ | BLK | P51451 | 1/20 | 0.85 |
| ▸ | BMX | P51813 | 1/20 | 0.85 |
| ▸ | JAK3 | P52333 | 1/20 | 0.85 |
| ▸ | ITK | Q08881 | 1/20 | 0.85 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.85 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16754833 | 1.00 | BTK (1.00) | BTKCYP2D6KCNH2ABCB11EGFR | |
| SCHEMBL16754812 | 0.94 | BTK (1.00) | BTKCYP2D6KCNH2ABCB11EGFR | |
| SCHEMBL30368308 | 0.94 | BTK (1.00) | BTKCYP2D6KCNH2ABCB11EGFR | |
| SCHEMBL17770658 | 0.93 | BTK (0.93) | BTKCYP2D6KCNH2ABCB11EGFR | |
| Remibrutinib SCHEMBL29564556 | 0.92 | BTK (1.00) | BTKCYP2D6KCNH2ABCB11EGFR | |
| Remibrutinib SCHEMBL29377382 | 0.92 | BTK (1.00) | BTKCYP2D6KCNH2ABCB11EGFR | |
| Remibrutinib SCHEMBL29395016 | 0.92 | BTK (1.00) | BTKCYP2D6KCNH2ABCB11EGFR | |
| Remibrutinib SCHEMBL16754888 | 0.92 | BTK (1.00) | BTKCYP2D6KCNH2ABCB11EGFR | |
| SCHEMBL16754897 | 0.90 | BTK (1.00) | BTKCYP2D6KCNH2ABCB11EGFR | |
| SCHEMBL29379703 | 0.90 | BTK (1.00) | BTKCYP2D6KCNH2ABCB11EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119732956-A | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119677725-A | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-113784957-B | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4441085-A2 | HIGH SELECTIVE CD229 ANTIGEN BINDING DOMAINS AND METHODS OF USE | University of Utah Research Foundation (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-4196478-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2023-06-21 | — | — | EP | disclosed |
| WO-2023102201-A2 | HIGH SELECTIVE CD229 ANTIGEN BINDING DOMAINS AND METHODS OF USE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2023-06-08 | — | — | WO | disclosed |
| CN-116157404-A | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | 诺华股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-110172056-B | Aminopyrimidine derivatives | 诺华股份有限公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3969441-A1 | NLRP3 INFLAMMASOME INHIBITORS | Novartis AG (CH) | 2022-03-23 | — | — | EP | disclosed |